Background: The EPIB 2012 study was conducted to compare the management of chronic hepatitis B (CHB) in HIV-positive and HIV-negative patients, its evolution over time and the relationship with the current presentation of CHB. Methodology: 755 consecutive patients with past or present CHB were seen in October 2012 in 19 French participating centers. All of their data were retrospectively collected from the first visit onwards through a standardized questionnaire. Out of these, 709 with known HIV status and with at least two HBV serological evaluations were analyzed. Results: The 299 HIV-positive patients were less likely to have full initial evaluation of CHB (9.7% vs. 42.9%, p<10-3), were followed for a longer duration (11.3+/-8.8 vs. 8.6+/-6.9 years, p<10-3) and more frequently treated for HBV (95.3% vs. 56.8%, p<10-3) than the 410 HBV-mono infected ones. Undetectable HBV at the last visit (80.8% in HIV-positive vs. 55.1% in HIV-negative patients, p<10-3) was positively associated in multivariate analysis with older age (OR + 1 year 1.03, 95%CI 1.01-1.05, p<10-3), lower baseline HBV DNA (OR + 1 log10IU/mL 0.87, 95%CI 0.80-0.95, p=0.001), longer duration of HBV therapy (OR + 1 month 1.03, 95%CI 1.02-1.03, p<10-3)and negatively with previous lamivudine monotherapy (OR 0.31, 95%CI 0.15-0.66, p=0.002), but not with HIV status. Similar efficacy was observed for tenofovir and entecavir, whatever the HIV serostatus. Renal impairment (creatinine clearance<60 ml/mn) was associated with older age and low baseline creatinine clearance, but not with HIV status. Cirrhosis was associated with age (OR + 1 year 1.06, 95%CI 1.04-1.09, p<10-3), male gender (OR 1.78, 95% CI: 0.93-3.41, p=0.08), daily alcohol intake>40g (OR 1.78, 95% CI: 1.14-2.78, p=0.01), and co-infection with HCV (OR 2.61, 95% CI: 1.11-6.26, p=0.03), HDV (OR 2.61, 95% CI: 1.07-6.36, p=0.03), but not with HIV. Hepatocellular carcinoma (HCC) was less frequent in HIV-positive patients (2/297, 0.7% vs 19/410, 4.7%, p=0.002), and was associated with older age (OR + 1 year 1.05, 95%CI 1.01-1.09, p=0.01), male gender (OR 10.00, 95%CI 1.27-78.60, p=0.03), and cirrhosis (OR 10.11, 95%CI 3.43 – 29.82, p<10-3), and negatively with HIV-positive status (OR 0.15, 95%CI 0.03-0.67, p=0.01). Conclusions: Even though the assessment of CHB still has to be improved, the negative impact of HIV on CHB seems to be disappearing probably due to the immunovirological impact of HAART and the more frequent and longer use of HBV therapy. The unexpected lower rate of HCC in HIV-positive patients suggests that a higher rate of viral suppression on long-term HBV therapy could reduce the risk. In light of these results, the management of chronic hepatitis B in HBV mono-infected patients and that in HIV-HBV co-infected patients could become closer in the near future.